NIPAL2

Across TCGA pan-cancer cohorts, NIPAL2 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of NIPAL2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where NIPAL2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NIPAL2 is over-expressed in tumor, although a few such as UCEC and HNSC show the opposite, repressed pattern.

KIRC, LIHC, and UCEC are the cancer types where NIPAL2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NIPAL2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+0.794	<.001	11	view →
LIHC	Female	II,III,IV	+1.605	<.001	9	view →
UCEC	All	All	−1.620	<.001	8	view →
THCA	Male	All	+0.591	<.001	7	view →
LUAD	Male	II,III,IV	+0.628	.009	4	view →
CHOL	All	All	+1.877	<.001	3	view →
HNSC	Male	II,III,IV	−0.614	.012	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

NIPAL2–KIRC

Open the KIRC breakdown →